News
Arrowhead said it is on track to earn the $100 million DM1 milestone soon and pocket the remaining $200 million by the end of the year. If Sarepta fails to make either payment, Arrowhead would ...
Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease treatment that is currently being considered for approval by Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results